CAJ | 학술논문

溶栓治疗目前是急性缺血性卒中最有效的治疗方法,发病3h内静脉给予重组组织型纤溶酶原激活剂是唯一被美国食品和药品监督管理局批准用于急性缺血性卒中治疗的药物.不过,由于静脉溶栓治疗的时间窗很短,只有极少数患者能在发病3h内到达医院并接受静脉溶栓治疗.因此,如何延长溶栓治疗时间窗,使更多的患者有机会接受溶栓治疗并从中获益,是学者们一直关注的问题.文章对近年来有关延长溶栓治疗时间窗的研究进展进行了综述.
용전치료목전시급성결혈성졸중최유효적치료방법,발병3h내정맥급여중조조직형섬용매원격활제시유일피미국식품화약품감독관리국비준용우급성결혈성졸중치료적약물.불과,유우정맥용전치료적시간창흔단,지유겁소수환자능재발병3h내도체의원병접수정맥용전치료.인차,여하연장용전치료시간창,사경다적환자유궤회접수용전치료병종중획익,시학자문일직관주적문제.문장대근년래유관연장용전치료시간창적연구진전진행료종술.
Currently,thrombolytic therapy is the most effective treatment for acute ischemic stroke.Intravenous recombinant tissue plasminogen activator administered within 3 hours of symptom onset is the only medication approved by U.S.Food and Drug Administration for the treatment of acute ischemic stroke.However,because the time window for intravenous thrombolytic therapy is very short,only a very few patients can reach the hospital for intravenous thrombolytic therapy within 3 hours of onset.Therefore,how to extend the time window of thrombolytic therapy for more patients to have accessed to it and benefit from it have been the concern of researchers.This article reviews about the recent advances in research on extending the time window of thrombolytic therapy.